应用重组人血小板生成素(rhTPO)临床观察

被引：19

作者：

黄梅

张东华

孙汉英

邓金牛

周剑锋

刘文励

机构：

[1] 华中科技大学同济医学院附属同济医院血液内科

来源：

中国血液流变学杂志 | 2005年 / 01期

关键词：

重组人血小板生成素(rhTPO); 血小板减少;

D O I：

暂无

中图分类号：

R55 [血液及淋巴系疾病];

学科分类号：

摘要：

目的　评价沈阳三生的重组人血小板生成素(rhTPO)对血小板减少患者的疗效和安全性。方法　11例血液恶性肿瘤患者和7例难治性ITP患者皮下注射rhTPO(1 0 μg/kg·d) ,动态监测注射后血小板生长情况。结果　肿瘤化疗组使用rhTP0 9d后,血小板计数较对照组明显升高(P <0 0 5 ) ,血小板恢复至10 0×10 9/L需19±9 4d ,较对照组2 4±6 .2d明显缩短。难治性ITP组显效6例,良好1例,总有效率10 0 %。无明显不良反应。结论　rhTPO对化疗后骨髓抑制引起的血小板减少及难治性ITP患者的血小板严重减少有促进增生作用,无明显不良反应

引用

页码：105 / 107

页数：3

共 7 条

[1] Thrombopoietin, but not erythropoietin promotes viability and inhibits apoptosis of multipotent murinehematopoietic progenitor cells in vitro. Borge OJ,Ramsfjell V,Veiby OP,et al. Blood . 1996
[2] The potential role of thrombopoietin in idiopathic thrombocytopenic purpura. Von dem BA,Folman C,linthorst G,et al. Blood Reviews . 2002
[3] Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Kaushansky K,Lok S,Holly RD,et al. Nature . 1994
[4] A randomized,double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor(PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Archimbaud E,Ottmann OG,Yin JA,et al. Blood . 1999
[5] Recombinant human thrombopoietin: basic biology and evalution of clinical studies. David J,Kuter and C,Glenn Begley. Blood . 2002
[6] Biological effect of pegylated recombinant human megakaryocyte growth and development factor(PEG-rHuMGDF) in patients with idiopathic thrombocytopenic purpura. Dan K,Nomura S,Hotta T,et al. Blood . 2001
[7] Safety and activity of recombinant human thrombopoietin (rhTPO) in patients(pts)with delayed platelet recovery(DPR). Nash R,Kurzrock R,Dipersio J,et al. Blood . 1997

← 1 →